Modified immune cells for resistant anca vasculitis
Part of Heart & circulation, Immune system & allergy, Infections clinical trials.
This trial tests a new type of cell therapy that uses your own immune cells, modified to target and calm the immune system, for people with severe ANCA vasculitis that hasn't improved with standard treatments. The goal is to reduce disease activity and potentially help you feel better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have been diagnosed with a type of blood vessel inflammation called ANCA vasculitis (either GPA or MPA).
- Your disease must be active, and you must have tried at least one standard treatment (like rituximab or cyclophosphamide) without success or you couldn't take it.
- You must not have had certain prior treatments like CAR T-cell therapy or a bone marrow transplant.
- You must not have severe organ damage (like very poor kidney or lung function) or active infections like hepatitis or HIV.
- You must agree to use effective birth control during the study and for 12 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy called CT1192 for people with ANCA-associated vasculitis, an autoimmune disease that causes blood vessel inflammation. The therapy aims to reset the immune system to stop the disease, and this early study focuses on safety and how the cells work in the body.
This trial tests a new type of cell therapy called CAR-T cells that target BCMA (a protein on certain immune cells) for people with two autoimmune diseases: ANCA-associated vasculitis and lupus nephritis. It is for patients whose disease has not responded to standard treatments or has come back after initial improvement.
This trial is testing a new therapy made from your own immune cells (called CAR NK cells) that are designed to fight a type of kidney disease that hasn't responded to standard treatments. It may be an option if you have membranous nephropathy, IgA nephropathy, or ANCA-associated vasculitis and previous treatments have failed.
This trial tests a new medicine called NM8074 for a type of blood vessel inflammation called ANCA-associated vasculitis. It's for people whose vasculitis is active and needs a stronger treatment like cyclophosphamide or rituximab.
This trial tests a new cell therapy called GT719 that targets B cells, part of the immune system that attacks the kidneys in several types of autoimmune kidney disease. It is designed for people whose kidney disease has not improved with standard treatments.
This trial tests a new type of immune cell therapy (CAR-γδT cells) that targets a protein called CD19 on your own B cells. It is for people with certain autoimmune diseases that have not gotten better with standard treatments. The goal is to see if this therapy can safely control the disease.
Hear when a new ANCA-IgG-positive ANCA Associated Vasculitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.